<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="fd76c55c-cb68-4884-8a1a-a4c6bf66562a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION. <br/>BRIMONIDINE tartrate ophthalmic solution, for topical ophthalmic use<br/>
      <br/>Initial U.S. Approval: 1996 <br/>
   </title>
   <effectiveTime value="20250322"/>
   <setId root="cdb8620f-adfa-4433-b285-9c42334f8600"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079947873" root="1.3.6.1.4.1.519.1"/>
            <name>Somerset Therapeutics, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="079947873" root="1.3.6.1.4.1.519.1"/>
                  <name>Somerset Therapeutics, LLC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="677236695" root="1.3.6.1.4.1.519.1"/>
                        <name>Somerset Therapeutics Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-231" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-232" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-231" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-232" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-231" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-232" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-231" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-232" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ab70872a-41cb-4a2e-875c-06c81ec0247a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250322"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-231" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>BRIMONIDINE TARTRATE</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>BRIMONIDINE TARTRATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70069-231-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190311"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208992" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190311"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>Clear, greenish-yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-232" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>BRIMONIDINE TARTRATE</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>BRIMONIDINE TARTRATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70069-232-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190311"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208992" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190311"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>Clear, greenish-yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-233" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>BRIMONIDINE TARTRATE</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>BRIMONIDINE TARTRATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70069-233-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190311"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208992" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190311"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>Clear, greenish-yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID265">
               <id root="abd34e99-b780-4ca2-8459-8281c57e256b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20231009"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID358">Brimonidine tartrate ophthalmic solution 0.2% is an alpha adrenergic agonist indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID268">
                     <id root="25e70deb-a05e-4033-ad8f-4d076c44b0cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID269">Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. </paragraph>
                        <paragraph>The IOP lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored. </paragraph>
                     </text>
                     <effectiveTime value="20231009"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID270">
               <id root="64322fc5-1442-4d10-95a6-170fcfe3e38e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20231009"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID274">One drop in the affected eye(s), three times daily, approximately 8 hours apart.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID271">
                     <id root="eae46e3d-52d6-413e-849e-4004ac84d52e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID272">The recommended dose is one drop of brimonidine tartrate ophthalmic solution 0.2% in the affected eye(s) three times daily, approximately 8 hours apart. </paragraph>
                        <paragraph>Brimonidine tartrate ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.  </paragraph>
                     </text>
                     <effectiveTime value="20231009"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID275">
               <id root="10cbc5b5-277d-4714-a7af-01bda30f866e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20190508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID279">Solution containing 2 mg/mL brimonidine tartrate.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID276">
                     <id root="1f24bbf0-22c3-4bae-aa62-b7630274d830"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID277">Solution containing 2 mg/mL brimonidine tartrate.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID280">
               <id root="d480fafe-8545-4645-976e-f69037396971"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20190508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID282">Neonates and infants (under the age of 2 years). (<linkHtml href="#ID283">4.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID283">
                     <id root="ac2eac36-c8f3-4aa3-bd14-e1ce8fdb77a0"/>
                     <title>4.1 Neonates and Infants (under the age of 2 years)</title>
                     <text>
                        <paragraph ID="ID284">Brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years) [<content styleCode="italics">see</content> <content styleCode="italics">Use</content> <content styleCode="italics">in</content> <content styleCode="italics">Specific</content> <content styleCode="italics">Populations</content> <content styleCode="italics">(<linkHtml href="#ID327">8.4</linkHtml>)</content>]<content styleCode="italics">.</content> </paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID285">
                     <id root="0e1a7f68-8d12-4ec6-84c2-1b5db62a9924"/>
                     <title>4.2 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph ID="ID286">Brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [<content styleCode="italics">see</content> <content styleCode="italics">Adverse</content> <content styleCode="italics">Reactions</content> <content styleCode="italics">(<linkHtml href="#ID303">6.1</linkHtml>)</content> <content styleCode="italics">and</content> <content styleCode="italics">(<linkHtml href="#ID306">6.2</linkHtml>)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID287">
               <id root="bfc759dd-f9a4-47a8-a380-1ae2579bd32a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250322"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID289">Potentiation of vascular insufficiency. (<linkHtml href="#ID290">5.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID290">
                     <id root="ae4999b6-798b-4499-8710-9b2a2cb408cf"/>
                     <title>5.1 Potentiation of Vascular Insufficiency</title>
                     <text>
                        <paragraph ID="ID291">Brimonidine tartrate ophthalmic solution may potentiate syndromes associated with vascular insufficiency. </paragraph>
                        <paragraph>Brimonidine tartrate ophthalmic solution should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID292">
                     <id root="2c38e3fa-99dc-4da0-b91c-fa8e42227a9d"/>
                     <title>5.2 Severe Cardiovascular Disease</title>
                     <text>
                        <paragraph ID="ID293">Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID355">
                     <id root="a0eec421-6b17-40fd-8272-cea74d7d8beb"/>
                     <title>5.3 Contamination of Topical Ophthalmic Products After Use</title>
                     <text>
                        <paragraph ID="ID356">There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#ID351">17</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID295">
                     <id root="26df4bb0-9d7f-4567-ab77-f966f2582fe9"/>
                     <title>5.4 Use with Contact Lenses</title>
                     <text>
                        <paragraph ID="ID296">The preservative in brimonidine tartrate ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling brimonidine tartrate ophthalmic solution to insert soft contact lenses. </paragraph>
                     </text>
                     <effectiveTime value="20250322"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID297">
               <id root="47e3e4fb-bf9f-4eb8-9901-4d6bdc3b7556"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250322"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID302">Most common adverse reactions occurring in approximately 10 to 30% of patients receiving brimonidine ophthalmic solution 0.2% included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. (<linkHtml href="#ID303">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact</content> <content styleCode="bold">Somerset</content> <content styleCode="bold">Therapeutics,</content> <content styleCode="bold">LLC</content> <content styleCode="bold">at 1-800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID298">
                     <id root="5314b6d7-1be5-4678-b410-e4ac0d0cf7f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID299">The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                        <list listType="unordered" ID="ID300" styleCode="Disc">
                           <item>Potentiation of Vascular Insufficiency <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                           </item>
                           <item>Severe Cardiovascular Disease <content styleCode="italics">[see Warnings and Precautions (&lt;5.2)]</content>
                           </item>
                           <item>Contamination of Topical Ophthalmic Products after Use <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                           </item>
                           <item>Neonates and Infants (under the age of 2 years) <content styleCode="italics">[see Contraindications (4.1)]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250322"/>
                  </section>
               </component>
               <component>
                  <section ID="ID303">
                     <id root="836a0e49-4652-4649-a0d5-eb866cba3ba2"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph ID="ID304">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <list listType="unordered" ID="ID305" styleCode="Disc">
                           <item>Adverse      reactions occurring in approximately 10-30% of the subjects (in descending      order): oral dryness, ocular hyperemia, burning and stinging, headache,      blurring, foreign body sensation, fatigue/drowsiness, conjunctival      follicles, ocular allergic reactions, and ocular pruritus.</item>
                           <item>Adverse      reactions occurring in approximately 3-9% of the subjects (in descending      order): corneal staining/erosion, photophobia, eyelid erythema, ocular      ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid      edema, conjunctival edema, dizziness, blepharitis, ocular irritation,      gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal      vision and muscular pain.</item>
                           <item>Adverse      reactions reported &lt; 3% of the patients: lid crusting, conjunctival      hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression,      hypertension, anxiety, palpitations/arrhythmias, nasal dryness and      syncope.</item>
                        </list>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID306">
                     <id root="e0e48b5d-6d80-45de-a031-a90e68d6162e"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID307">The following reactions have been identified during postmarketing use of brimonidine tartrate ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, or a combination of these factors, include:</paragraph>
                        <list listType="unordered" ID="ID308" styleCode="Disc">
                           <item>Bradycardia;      conjunctivitis; hypersensitivity; hypotension; iritis;      keratoconjunctivitis sicca; lacrimation increased; miosis; nausea; skin      reactions (including erythema, eyelid pruritus, rash, and vasodilation);      and tachycardia.</item>
                           <item>Apnea,      bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor,      respiratory depression, and somnolence in infants receiving brimonidine      tartrate ophthalmic solutions.</item>
                        </list>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID309">
               <id root="51191aa6-6467-4576-acdf-6198be387097"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250322"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID311" styleCode="Disc">
                           <item>Antihypertensives/cardiac glycosides may      lower blood pressure. (<linkHtml href="#ID312">7.1</linkHtml>)</item>
                           <item>Use with CNS depressants may result in an      additive or potentiating effect. (<linkHtml href="#ID314">7.2</linkHtml>)</item>
                           <item>Tricyclic antidepressants may potentially      blunt the hypotensive effect of systemic clonidine. (<linkHtml href="#ID316">7.3</linkHtml>)</item>
                           <item>Monoamine oxidase inhibitors may result      in increased hypotension. (<linkHtml href="#ID318">7.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID312">
                     <id root="857a56db-7710-421c-b8bd-1bf87ed84970"/>
                     <title>7.1 Antihypertensives/Cardiac Glycosides</title>
                     <text>
                        <paragraph ID="ID313">Because brimonidine tartrate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution is advised. </paragraph>
                     </text>
                     <effectiveTime value="20250322"/>
                  </section>
               </component>
               <component>
                  <section ID="ID314">
                     <id root="6b279736-ed21-495c-adc4-2cbc1e333cd5"/>
                     <title>7.2 CNS Depressants</title>
                     <text>
                        <paragraph ID="ID315">Although specific drug interaction studies have not been conducted with Brimonidine tartrate ophthalmic solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. </paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID316">
                     <id root="72f3b8e5-dd80-4fa6-8e5a-45d8f2a3fd59"/>
                     <title>7.3 Tricyclic Antidepressants</title>
                     <text>
                        <paragraph ID="ID317">Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with Brimonidine tartrate ophthalmic solution in humans can lead to resulting interference with the IOP lowering effect. Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID318">
                     <id root="9c3928a4-155a-41e8-991e-1f55c7f410ef"/>
                     <title>7.4 Monoamine Oxidase Inhibitors</title>
                     <text>
                        <paragraph ID="ID319">Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID320">
               <id root="8e4874b9-b369-4226-a4c5-9be54c363c82"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20190508"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID322">Use with caution in children ≥ 2 years of age. (<linkHtml href="#ID327">8.4</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID323">
                     <id root="ed2e56b5-40c8-4a40-9edb-efed7e91bed8"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID324">Pregnancy Category B: Teratogenicity studies have been performed in animals.</paragraph>
                        <paragraph>Brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. The highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5 mg/kg/day) achieved AUC exposure values 375-fold higher or 19-fold higher, respectively, than similar values estimated in humans treated with Brimonidine tartrate ophthalmic solution 0.2%, one drop in one eye, twice daily.</paragraph>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent.</paragraph>
                        <paragraph>Because animal reproduction studies are not always predictive of human response, Brimonidine tartrate ophthalmic solution should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. </paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID325">
                     <id root="2a056f75-ce09-4e0a-99c5-9220c83a47e1"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID326">It is not known whether brimonidine tartrate is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk. Because of the potential for serious adverse reactions from Brimonidine tartrate ophthalmic solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID327">
                     <id root="7c2fea31-ae4e-4fc9-a1f0-daf9bf1726f8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID328">Brimonidine tartrate ophthalmic solution is contraindicated in children under the age of 2 years <content styleCode="italics">[see</content> <content styleCode="italics">Contraindications</content> <content styleCode="italics">(<linkHtml href="#ID283">4.1</linkHtml>)]</content>. During postmarketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine. The safety and effectiveness of brimonidine tartrate have not been studied in children below the age of 2 years.</paragraph>
                        <paragraph>In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse reactions with Brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence (50-83% in patients ages 2 to 6 years) and decreased alertness. In pediatric patients 7 years of age (greater than 20 kg), somnolence appears to occur less frequently (25%). Approximately 16% of patients on Brimonidine tartrate ophthalmic solution 0.2% discontinued from the study due to somnolence.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID329">
                     <id root="9f486b51-c8ac-4d8c-8cb4-aa87d0ecac21"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID330">No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID331">
                     <id root="ba04c5c4-571f-4a39-9ea5-910409009720"/>
                     <title>8.6 Special Populations</title>
                     <text>
                        <paragraph ID="ID332">Brimonidine tartrate ophthalmic solution has not been studied in patients with hepatic impairment.</paragraph>
                        <paragraph>Brimonidine tartrate ophthalmic solution has not been studied in patients with renal impairment. The effect of dialysis on brimonidine pharmacokinetics in patients with renal failure is not known.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID333">
               <id root="786d067d-764c-4608-92fd-21f36a517d9c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID334">Very limited information exists on accidental ingestion of brimonidine in adults; the only adverse reaction reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine tartrate as part of medical treatment of congenital glaucoma or by accidental oral ingestion <content styleCode="italics">[see</content> <content styleCode="italics">Use</content> <content styleCode="italics">In</content> <content styleCode="italics">Specific</content> <content styleCode="italics">Populations</content> <content styleCode="italics">
                        <linkHtml href="#ID327">(8.4</linkHtml>)]</content>. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.</paragraph>
               </text>
               <effectiveTime value="20190508"/>
            </section>
         </component>
         <component>
            <section ID="ID335">
               <id root="43bc6d9f-da38-470b-b9d4-9a07de3617a2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID336">Brimonidine tartrate ophthalmic solution 0.2%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist (topical intraocular pressure lowering agent).</paragraph>
                  <paragraph>The structural formula of brimonidine tartrate is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID338">5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; MW= 442.24</paragraph>
                  <paragraph>In solution, brimonidine tartrate ophthalmic solution 0.2% has a clear, greenish-yellow color. It has an osmolality of 280 -330 mOsml/kg and a pH of 5.6 -6.6.</paragraph>
                  <paragraph>Each mL of brimonidine tartrate ophthalmic solution contains the active ingredient brimonidine tartrate 0.2% (2 mg/mL) with the inactive ingredients benzalkonium chloride 0.005% (0.05 mg/mL) as a preservative; citric acid; polyvinyl alcohol; sodium chloride; sodium citrate; and water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH.</paragraph>
               </text>
               <effectiveTime value="20250322"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Molecular structure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID339">
               <id root="f257213c-e78a-4f8a-a36b-cd65881ae6ce"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20190508"/>
               <component>
                  <section ID="ID340">
                     <id root="7c7b2a81-d290-4cab-a43b-81d65e4e4f23"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID341">Brimonidine tartrate ophthalmic solution 0.2% is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing.</paragraph>
                        <paragraph>Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
               <component>
                  <section ID="ID342">
                     <id root="33ee298e-e40d-4d1e-81d9-10d1d8cb2b3d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID357">
                           <content styleCode="bold">Absorption</content>
                        </paragraph>
                        <paragraph>After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>The protein binding of brimonidine has not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism</content>
                        </paragraph>
                        <paragraph>In humans, brimonidine is extensively metabolized by the liver.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Excretion</content>
                        </paragraph>
                        <paragraph>Urinary excretion is the major route of elimination of brimonidine and its metabolites. Approximately 87% of an orally-administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID343">
               <id root="50affa5c-4686-47cf-82d9-c95181e6b0be"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20190508"/>
               <component>
                  <section ID="ID344">
                     <id root="7c5b54a3-d443-4b1d-876a-33adedf99b4b"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID345">No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1.0 mg/kg/day in rats achieved ~77 and 118 times, respectively, the plasma C<sub>max</sub> drug concentration estimated in humans treated with one drop Brimonidine tartrate ophthalmic solution 0.2% into both eyes 2 times per day<content styleCode="bold">.</content>
                        </paragraph>
                        <paragraph>Brimonidine tartrate was not mutagenic or clastogenic in a series of <content styleCode="italics">in</content> <content styleCode="italics">vitro</content> and <content styleCode="italics">in</content> <content styleCode="italics">vivo</content> studies including the Ames bacterial reversion test, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, and three <content styleCode="italics">in</content> <content styleCode="italics">vivo</content> studies in CD-1 mice: a host-mediated assay, cytogenetic study, and dominant lethal assay.</paragraph>
                        <paragraph>A reproduction and fertility study in rats with brimonidine tartrate demonstrated no adverse effect on male or female fertility at oral doses up to 1 mg/kg, estimated as approximately 200 times the systemic exposure (AUC) following the maximum recommended human ophthalmic dose of Brimonidine tartrate ophthalmic solution 0.5%.</paragraph>
                     </text>
                     <effectiveTime value="20190508"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID346">
               <id root="1201b7e1-ad5a-4472-a687-19b653eda467"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID347">Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.</paragraph>
                  <paragraph>In comparative clinical studies with timolol 0.5%, lasting up to one year, the IOP lowering effect of brimonidine tartrate ophthalmic solution was approximately 4-6 mm Hg compared with approximately 6 mm Hg for timolol. In these studies, both patient groups were dosed BID; however, due to the duration of action of brimonidine tartrate ophthalmic solution, it is recommended that brimonidine tartrate ophthalmic solution be dosed TID. Eight percent of subjects were discontinued from studies due to inadequately controlled intraocular pressure, which in 30% of these patients occurred during the first month of therapy. Approximately 20% were discontinued due to adverse experiences.</paragraph>
               </text>
               <effectiveTime value="20250322"/>
            </section>
         </component>
         <component>
            <section ID="ID348">
               <id root="8847d1c5-921e-4d5b-89b4-ba48bfdb426a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID349">Brimonidine tartrate ophthalmic solution 0.2% is supplied sterile, in white LDPE Bottle, White LDPE Nozzle with a Purple HDPE Cap in the following sizes: </paragraph>
                  <paragraph>5 mL bottle in one carton – NDC 70069-<content styleCode="bold">231</content>-01</paragraph>
                  <paragraph>10 mL bottle in one carton – NDC 70069-<content styleCode="bold">232</content>-01</paragraph>
                  <paragraph>15 mL bottle in one carton – NDC 70069-<content styleCode="bold">233</content>-01 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store at 15<sup>o</sup>-25<sup>o</sup>C (59<sup>o</sup>-77<sup>o</sup>F).</paragraph>
               </text>
               <effectiveTime value="20190508"/>
            </section>
         </component>
         <component>
            <section ID="ID350">
               <id root="6696735f-8e74-4ee3-bec6-0ef62e3198b8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID351">
                     <content styleCode="bold">Handling</content> <content styleCode="bold">the</content> <content styleCode="bold">Container</content>
                  </paragraph>
                  <paragraph>Instruct patients that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions <content styleCode="italics">[see</content> <content styleCode="italics">Warnings</content> <content styleCode="italics">and</content> <content styleCode="italics">Precautions</content> <content styleCode="italics">(<linkHtml href="#ID355">5.3</linkHtml>)]</content>. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.</paragraph>
                  <paragraph>
                     <content styleCode="bold">When</content> <content styleCode="bold">to</content> <content styleCode="bold">Seek</content> <content styleCode="bold">Physician</content> <content styleCode="bold">Advice</content>
                  </paragraph>
                  <paragraph>Advise patients that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container<content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Use</content> <content styleCode="bold">with</content> <content styleCode="bold">Contact</content> <content styleCode="bold">Lenses</content> </paragraph>
                  <paragraph>Advise patients that contact lenses should be removed prior to instillation of Brimonidine tartrate ophthalmic solution and may be reinserted 15 minutes following its administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Use</content> <content styleCode="bold">with</content> <content styleCode="bold">Other</content> <content styleCode="bold">Ophthalmic</content> <content styleCode="bold">Drugs</content>
                  </paragraph>
                  <paragraph>Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Potential</content> <content styleCode="bold">for</content> <content styleCode="bold">Decreased</content> <content styleCode="bold">Mental</content> <content styleCode="bold">Alertness</content>
                  </paragraph>
                  <paragraph>As with other similar medications, Brimonidine tartrate ophthalmic solution may cause fatigue and/or drowsiness in some patients. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>Somerset Therapeutics, LLC</paragraph>
                  <paragraph>Somerset, NJ 08873</paragraph>
                  <paragraph>Customer Care # 1-800-417-9175</paragraph>
                  <paragraph>Made in India</paragraph>
                  <paragraph>Code No.:KR/DRUGS/KTK/28/289/97</paragraph>
                  <paragraph>ST-BRM/P/05</paragraph>
                  <paragraph>1201040</paragraph>
               </text>
               <effectiveTime value="20250322"/>
            </section>
         </component>
         <component>
            <section ID="ID352">
               <id root="e2d90d90-63a5-42f8-af76-92414643e428"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID359">5 mL Container label</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID360">5 mL Carton label</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID362">10 mL Container label</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph ID="ID364">10 mL Carton label</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph ID="ID366">15 mL Container label</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph ID="ID368">15 mL Carton label</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20250322"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>5 ml bottle label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>5 mL Carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>10 mL Container label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>10 mL Carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>15 mL Container label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>15 mL Carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fd76c55c-cb68-4884-8a1a-a4c6bf66562a-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>